|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 771.5 USD | +0.05% |
|
+1.44% | +32.26% |
| 10:54am | Roche: share price stands out, Deutsche Bank in support | CF |
| May. 16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
April 30 (Reuters) - Eli Lilly beat Wall Street estimates for first-quarter profit on Tuesday, helped by rising demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro.
The Indianapolis-based drugmaker posted a profit of $2.58 per share on an adjusted basis, compared with analysts' expectations of $2.46 per share, according to LSEG data. (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru and Patrick Wingrove in New York; Editing by Devika Syamnath)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 903.3 DKK | -1.05% | -0.73% | 593B | ||
| 771.6 USD | +0.06% | +1.46% | 694B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +32.29% | 694B | |
| +29.39% | 593B | |
| -1.58% | 371B | |
| +19.94% | 331B | |
| +7.29% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.73% | 169B | |
| -0.66% | 164B |
ELI LILLY AND COMPANY 
